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Background 
Cancer is often associated with chronic anemia which frequently requires 
blood transfusions. This study was performed to assess the efficacy and safety of r-
HuEPO therapy in children with cancer. 
 
Patients and methods 
Twenty-five patients under 18 years of age with solid malignant tumors were treated 
with 150 U/kg/day of r-HuEPO 5 times weekly for 12 weeks. Response was defined as 
an increase of the baseline hemoglobin level by at least 2 g/dl. r-HuEPO patients were 
compared to 25 matched historical controls. 
 
Results 
Response was achieved in 72% of r-HuEPO patients. Hemoglobin level increased from 
9.8 ± 0.6 g/dl at baseline to 12.4 ± 1.7 g/dl at the end of treatment in the r-HuEPO group 
and increased from 9.5 ± 0.7 g/dl to 9.6 ± 1.4 g/dl in the control group (P < .001, 
Student’s t-test). Only 16% of patients receiving r-HuEPO required blood transfusions 
vs 96% of control patients (P < .001, Student’s t-test), with mean units of blood 
transfused per patient being 0.35 in the r-HuEPO group and 3.56 in controls (P < .001, 
Student’s t-test). There was a statistically significance improvement in Karnofsky’s 
index in r-HuEPO patients. No adverse reaction related to r-HuEPO therapy was 
observed. 
 
Conclusions  
r-HuEPO is a safe and effective means of increasing hemoglobin level and reducing 
blood requirements in children with solid malignant tumors receiving chemotherapy.  
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INTRODUCTION 
 
Anemia is commonly observed in cancer patients before any myelosuppressive therapy 
is administered, and may be multifactorial in origin [1]. Nutritional deficiencies, 
chemotherapy, radiation, bone marrow infiltration, hemorrhages, sequestration in an 
enlarged spleen, or hemolysis may cause anemia [2], but anemia of chronic disease 
probably plays the fundamental role in most anemic cancer patients [3,4] with an 
inadequate erythropoietin (EPO) response to the degree of anemia [5]. 
 
Cancer patients with symptoms of anemia frequently require red cell transfusions [6], 
which carry significant risks in up to 20% of cases [7–10]. Since recombinant human 
erythropoietin (r-HuEPO) became available, it has been safely and successfully used in 
anemic patients with renal disease [11], in AIDS patients treated with zidovudine [12], 
after bone marrow transplantation [13], for rheumatoid arthritis [14], and for 
chemotherapy-induced anemia in adult cancer patients [15,16]. We report a pilot study 
to evaluate the clinical utility of r-HuEPO as an alternative to blood transfusion for 
anemia in pediatric cancer patients receiving chemotherapy. 
 
 
 
PATIENTS AND METHODS 
 
The trial was an open-label, single-institution, pilot study of safety and efficacy. The 
protocol was approved by the Ethics Committee of our hospital and written informed 
consent was obtained from at least one parent or a legal representative of all patients. 
 
 
Patients and Historical Controls 
 
The study concerns patients under 18 years of age with a diagnosis of solid malignancy 
confirmed by biopsy specimen, who received cyclic combination chemotherapy for a 
total of at least 5 days every 3–4 weeks. Prior to study all patients had a life expectancy 
of at least 3 months, and had been clinically stable for at least 1 month. Laboratory 
values for inclusion were as follows: hemoglobin (Hb) concentration < 10.5 g/dl, 
absolute neutrophil count (ANC) > 0.5 × 103 cells/µl, platelet count >75 × 103 cells/µl, 
reticulocyte count < 3%, creatinine concentration < 2.0 mg/dl, serum calcium level        
< 12.0 mg/dl, serum folate, vitamin B12, AST, ALT, bilirubin, and urine analysis within 
normal limits, ferritin > 30 ng/ml, transferrin saturation > 15%, negative Coombs’ test 
and stool negative for occult blood. Exclusion criteria were: known cerebral metastases, 
uncontrolled hypertension, seizures, causes of anemia other than chronic neoplastic 
disease (such as folate and vitamin B12 deficiency, iron deficiency, gastrointestinal 
bleeding, hemolysis, ...), acute illness within 7 days of study entry, experimental therapy 
or surgical treatment within 30 days of study entry. 
 
Patients were compared to matched historical controls. Protocols of chemotherapy were 
continued and unmodified during the study. Standard clinical practices and 
chemotherapy protocols were similar in both groups. 
 
 
 
Treatment Regimen 
 
The r-HuEPO was supplied by Boehringer Mannheim, Barcelona, Spain, and 
administered subcutaneously in a dose of 150 U/kg/day 5 times weekly for 12 
consecutive weeks. Oral iron supplements were commenced if serum ferritin fell to 
<100 ng/ml and/or transferrin saturation fell to <20%. 
 
 
Clinical and Laboratory Monitoring 
 
Medical history and physical examination, a complete blood cell count, reticulocyte 
count, determinations of serum iron, ferritin, transferrin saturation, folate, vitamin B12, 
electrolytes, glucose, ALT, AST, bilirubin, performance status according to 
Karnofsky’s index [17], and blood transfusion information were recorded at baseline, 
every 3–4 weeks (chemotherapy cycle), and at the end of study. Baseline assessments 
also included 12-lead electrocardiogram, chest x-rays, urinalysis, test of stool for occult 
blood, and serum EPO level measured by radioimmunoassay (Diagnostic Systems 
Laboratories, Texas, USA). To define EPO levels as appropriate or inappropriate for a 
given degree of anemia, the observed/ predicted log (serum EPO) ratio (O/P ratio) was 
calculated [18]. The predictive value of EPO for a given degree of anemia was 
determined by a regression equation obtained by Beguin et al. [19] from reference 
subjects. During r-HuEPO therapy, weekly assessment of blood pressure and pulse and 
respiratory rates were performed. 
 
 
Transfusion Practice and Intensity of Chemotherapy 
 
Red cell transfusions were performed if Hb level fell to <9 g/dl and/or symptoms of 
anemia were developed. The transfusion trigger was determined in both r-HuEPO and 
control groups to ensure that results were not influenced by differential transfusion 
practice. The Hb threshold of 9 g/dl might be regarded as relatively high for blood 
transfusion. However, this trigger was chosen because ours is a reference department for 
Pediatric Oncology and most of the patients live far from the hospital with an average 
distance of 350 kilometers. Therefore, an urgent treatment of anemia cannot be 
undergone when patients are between hospitalization periods. 
 
The intensity of chemotherapy was measured in order to account for the possible effects 
on our results of differences in intensity between the r-HuEPO and control group. Since 
the patients received a wide variety of different chemotherapy regimens, a surrogate 
marker for the intensity of chemotherapy was used. The most appropriate marker 
appeared to be the effect of chemotherapy on neutrophil and platelet counts. Therefore, 
the determinations included the number of episodes in which ANC fell to <1000 or 
<500 cells/ml and platelet count fell to <50000 or 20000 cells/ml (15). 
 
 
Response Criteria 
 
“Response” was defined as an increase of Hb of at least 2 g/dl with respect to the 
baseline level within 12 weeks without red cell transfusions [20,21]. 
 
Evaluation of Toxic Effects 
 
Any abnormal vital signs or clinically significant abnormal laboratory findings were 
recorded for consideration as toxic effect. 
 
 
Statistical Evaluation 
 
Statistical inference for dichotomous variables formulated as 2 × 2 tables was carried 
out using Fischer’s Exact Test. Analysis of variance was used to compare repetitive 
measurements. Two-sample t-tests were used to compare means between groups, and 
paired t-tests were used to test changes from baseline to other values. All statistical tests 
of hypotheses were two-sided and were carried out at the α = 0.05 level. 
 
 
 
RESULTS 
 
Demographic and Baseline Characteristics 
 
A total of 25 patients were enrolled into the study between February 1994 and May 
1995 and received r-HuEPO therapy. All of them completed the 12 weeks of treatment. 
The historical control group included 25 patients treated in our department between 
September 1992 and January 1994. The demographic and baseline characteristics of 
both groups are listed in Table I. There were no statistically significant differences 
between groups for these data. 
 
 
Hematologic Measurements 
 
The kinetics of Hb levels are shown in Figure 1a. Baseline mean ± SD Hb level was 
similar (P = .80) in both groups: 9.8 ± 0.6 g/dl in r-HuEPO group and 9.5 ± 0.7 g/dl in 
controls. The Hb level of r-HuEPO group increased relative to the control group and 
this increase was statistically significant by week 6 (11.9 ± 2.2 vs. 10.4 ± 1.2 g/dl; P = 
.023), at week 9 (11.7 ± 2.1 vs. 10.2 ± 1.3 g/dl; P = .039) and at the end of therapy (12.4 
± 1.7 vs. 9.6 ± 1.4 g/dl; P < .001). No relationship was observed between Hb level and 
type of tumor nor the presence of bone marrow metastases. There were no statistically 
significant differences in response to r-HuEPO as a function of the severity of the 
anemia. 
 
In the r-HuEPO group the median absolute reticulocyte count increased from 60000/µl 
(baseline value) to 126296/µl at week 6 (P = .011), 156185/µl at week 10 (P = .003), 
and 134678/µl at the end of study (P = .007). There were no significant differences 
between groups regarding mean corpuscular volume, mean corpuscular Hb, mean 
corpuscular Hb concentration, white blood count, and platelets. 
 
 
 
 
 
Serum EPO Levels 
 
Mean serum EPO level was 42.6 mU/ml (range: 7.8– 134.4) at baseline in the r-HuEPO 
group. Endogenous EPO production, measured by O/P ratio, was appropriate for the 
degree of anemia in only 3 patients (Table I). No data on EPO were available in the 
control group. 
 
 
Intensity of Chemotherapy 
 
Intensity of chemotherapy (as measured by neutrophil and platelet counts) for r-HuEPO 
and control patients was not significantly different (P > .05) (Table I). 
 
 
Transfusion Requirements 
 
The percentages of patients transfused before entry into the study were 80% in the r-
HuEPO group and 84% in the control group (Figure 2a), the mean number of units of 
blood per patient being 2.3 (range: 0–10) and 2.5 (range: 0–7), respectively (Figure 2b). 
These differences at baseline were not statistically significant. During the study, the 
percentages of patients requiring blood transfusion were 16% (4 out of 25) in the r-
HuEPO group and 96% (24 out of 25) in the control group (Figure 2a), the mean 
number of units of blood transfused per patient being 0.35 (range: 0–4) and 3.56 (range: 
0–8), respectively (Figure 2b). These differences between the groups were statistically 
significant (P < .001). The mean Hb level at which patient were given transfusions was 
8.8 g/dl in r-HuEPO group and 8.9 g/dl in controls (P > .05). 
 
 
Response 
 
In the r-HuEPO group, 18 patients responded by increases of at least 2 g/dl in Hb level, 
without requiring blood transfusion. Most responders achieved the necessary increase in 
Hb level between the fourth and eighth weeks of therapy. 
 
 
Karnofsky’s Index 
 
The mean baseline values of Karnofsky’s index were 70.8% in r-HuEPO group and 
71.2% in controls (P > .05). In the r-HuEPO group there was a statistically significant 
improvement (P < .05) in Karnofsky’s index between the start and the end of the study 
(Figure 1b). No such improvement was seen in the control group. Of the 15 r-HuEPO 
patients whose Karnofsky’s index improved, 13 were responders and 2 were non-
responders. 
 
 
Iron Parameters 
 
Serum ferritin level was high at baseline in the r-HuEPO group (probably due to 
pretransfusions) (307 ng/ ml; range: 25–1200). Changes in serum ferritin concentrations 
during the study fell to reach the limit of statistical significance at week 3 (P = .028) and 
week 6 (P = .049), increasing after weeks 9 and 12, but with no statistical significance 
(P > .05). Transferrin saturation followed a parallel evolution during the study. Fourteen 
(56%) patients in r-HuEPO group required iron supple-mentation during a mean time of 
7.2 weeks (range: 3– 12). 
Safety 
 
Treatment was well tolerated. No patient was removed from the study because of r-
HuEPO-related toxicity. No severe adverse effect was reported. 
 
  
Other Effects 
 
No statistical differences between the groups regarding electrolytes, serum creatinine, 
glucose, bilirubin, AST, and ALT were observed. 
 
 
 
DISCUSSION 
 
Anemia is common in cancer patients and red blood cell transfusions are often required. 
Transfusions are still associated with some adverse reactions and another problem may 
be represented by religious beliefs. Although the mechanism of cancer-related anemia is 
not well known, it appears that an inadequated EPO response plays a fundamental role 
[5]. Recently, some studies have been performed using r-HuEPO to treat anemia in 
adult cancer patients [15,16,21,22]. To confirm and extend the outcome of these results, 
we performed this pilot study in pediatric cancer patients. 
 
The present study demonstrates that r-HuEPO increases the Hb level in pediatric cancer 
patients receiving chemotherapy. The increase in Hb concentration from baseline to the 
end of study was greater in r-HuEPO treated patients than in controls. This result is in 
accordance with those reported in the literature [15,16,20–24]. However, in pediatric 
patients the published data is controversial. Nenadov Beck et al. [25] conclude that r-
HuEPO administration was safe but ineffective, probably due to a mechanism of 
transient primary resistance. On the other hand, similar results to ours have been 
reported by Locatelli et al. [18] in children with acute leukemia given allogeneic bone 
marrow transplantation, and by Kronberger et al. [26] in pediatric patients with Ewing’s 
sarcoma and osteosarcoma. 
 
We did not observe any statistically significant correlation between increase in Hb 
levels and tumor type in our study, but this is not very indicative, given the limited 
number of cases of each tumor type and the fact that hematological malignancies were 
not included. Interestingly, neither tumor type nor bone marrow involvement appeared 
to influence the response to r-HuEPO therapy [27]. Patients with hematologic and solid 
tumors respond equally well to r-HuEPO [15]. 
 
r-HuEPO has been shown to promote both granulocyte and megakaryocyte colony 
growth [28,29]. In our study, as in others [18,22], there were no significant differences 
between the r-HuEPO group and control group in either white blood cell or platelet 
counts. 
 
The transfusion history of the patients was almost identical in the r-HuEPO and control 
groups, but subsequent to the improvement in Hb levels in r-HuEPO treated patients 
there was a reduction in the transfusion requirements of this group. This reduction is 
consistent with the findings of other authors [16,18,21,30,31]. Abels [15] observes that 
transfusion rates were reduced after 1 month of r-HuEPO therapy, suggesting that this 
lag in response was probably related to the time required for the stimulation of 
erythropoiesis to be reflected in decreased transfusion practice. 
 
Response was achieved in 72% of r-HuEPO patients. Tumor type and bone marrow 
involvement did not appear to influence the response rate. This response percentage is 
not associated with differential transfusion practice between groups, nor with a 
differential intensity of chemotherapy. The response rates in published studies are in 
accordance with our findings, and range from 31.7% [15] to 82–85% [16,32], reflecting 
differences in dose, route of administration, duration of therapy, the response criteria 
used, and the patient population under study [27]. 
 
Although most patients in this study had a favorable Karnofsky’s index at baseline, the 
r-HuEPO patients achieved a statistically significant improvement of their scores from 
the third week of treatment. This observed improvement is in accordance with reports 
on the effect of r-HuEPO therapy in patients with end-stage renal disease [33], and in 
adult cancer patients [15,21,31,34]. Improvements in quality of life of patients with 
response to therapy may be explained by the clinically observable subsiding of all or 
most symptoms of anemia [34]. Even two patients with no response to r-HuEPO 
treatment had some significant improvement during therapy, as reported by Leitgeb et 
al. [34] and Ludwig et al. [21], probably due to placebo effect or marginal beneficial 
effects of the treatment. 
 
In accordance with other reports [16,21,25], r-HuEPO treatment was excellently 
tolerated by all patients, causing no severe adverse reaction. No patient complained of 
the local burning sensation at the site of injection primarily related to epoetin-α 
administration. Although hypertension in cancer patients receiving r-HuEPO has been 
reported [22], it is less frequent and of easier management than in renal patients [11]. 
 
 
 
CONCLUSIONS 
 
This study demonstrates that r-HuEPO therapy is a safe and effective means of 
increasing Hb level and reducing blood requirements in pediatric patients with 
malignant solid tumors receiving chemotherapy. 
 
On the basis of this data, we suggest that more extensive trials in pediatric cancer 
patients should be embarked upon in order to clarify the effect on transfusion 
requirements, to define the optimal dose and to identify prediction factors for response 
to r-HuEPO therapy. 
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Table 1. Demographic and Baseline Characteristics 
Parameter r-HuEPO* Control* 
Number of patients 25 25 
Sex   
Male 14 14 
Female 11 11  
Mean age, y (range) 12.6 (6–17) 11.8 (5–17) 
Mean ± SD weight (kg) 49.4 ± 16.1 44.3 ± 16.6 
Mean ± SD height (cm) 156 ± 16.1 148.8 ± 19.6 
Mean ± SD Hb level (g/dl) 9.8 ± 0.6 9.5 ± 0.7 
Mean ± SD WBC count (×µl) 5904 ± 3170 7517 ± 3080 
Mean ± SD platelet count (×µl) 256000 ± 72000 254000 ± 69000 
Mean serum EPO, mU/ml (range) 42.6 (7.8–134.4)  
Mean O/P ratio (range) 0.7 (0.44–1.08)  
O/P ratio <1 (% of patients) 88  
Tumor type (%)   
Ewing’s sarcoma 36 40 
Ostesarcoma 32 32 
CNS tumors 16 16 
Hodgkin’s lymphoma 8 8 
Rhabdomyosarcoma 4 4 
Unknown primary site 4  
N of episodes with ANC <1000 cells/µl 14 12 
N of episodes with ANC <500 cells/µl 20 18 
N of episodes with platelets <50000/µl 11 7 
N of episodes with platelets <20000/µl 4 5 
*No statistically significant differences (P > .05) between groups. 
y: years; Hb; hemoglobin; WBC: white blood cell; CNS: central nervous system; O/P 
ratio: observed/predicted log (serum EPO) ratio; N: number of data; ANC: absolute 
neutrophil count. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1. Changes in hemoglobin levels (a) and Karnofsky’s index (b) in both groups 
during study. *P < .05, Student’s t-test. 
 
 
 
 
 
Figure 2. Percentage of patients (a) and mean number of units transfused per patient (b) 
before (left columns) and during (right columns) study period. *P > .05; †P < .001, 
Student’s t-test. 
 
 
 
